Meg Barbor, MPH

The government now expects healthcare providers and suppliers to have effective compliance programs in place, but a compliance plan only works for you when you are working with it, according to Robert W. Liles, JD, MBA, MS, Managing Partner, Liles Parker, PLLC, Washington, DC, and Paul Weidenfeld, JD, Co-Founder, Exclusion Screening, Washington, DC, who hosted a lively discussion on the ins and outs of effective compliance plans and the laws surrounding them at the virtual 2020 Healthcare Administration Alliance Conference. Read More ›

The COVID-19 pandemic has led to a massive boom in telehealth, according to Heidi Kocher, Esq, Partner, Liles Parker, PLLC, Plano, TX. When lockdowns began to be enforced around the world, providers needed to make rapid and unprecedented changes to the way they delivered care, and healthcare teams and patients alike were required to quickly adapt to telehealth and telemedicine. Read More ›

Social distancing, stay-at-home orders, and “the new normal.” We are all adapting to the changes brought about by COVID-19, but what does it mean for cancer care? At the virtual 2020 Community Oncology Alliance (COA) Community Oncology Conference, Bo Gamble, Director, Strategic Practice Initiatives, COA, asked a panel of experts to predict how the current climate will shape challenges for community oncologists in the future.

Read More ›

A Medically Integrated Pharmacy Care (MIPC) model represents the true integration of pharmaceutical and medical oncology care. At the virtual 2020 Community Oncology Alliance (COA) Community Oncology Conference, Jim Schwartz, RPh, Executive Director, Pharmacy Operations, Texas Oncology, Dallas, discussed this model, which he said provides clarity of focus around complex disease states.

Read More ›

Breast cancer doctors got it right a long time ago when they began characterizing malignancies with classifications such as hormone-receptor and HER2 status, according to Alexander Spira, MD, PhD, FACP, Medical Oncologist, Virginia Cancer Specialists, Fairfax.

Read More ›

A biosimilar is a “highly similar” copy of a biologic drug, but it is not a generic. This definition understandably causes confusion among patients and providers alike, but it is an important distinction, according to Jim Koeller, MS, FHOPA, Professor, Pharmacotherapy, The University of Texas at Austin. Read More ›

Although medicinal cannabis has been used successfully as a palliative therapy in patients with cancer, it is still stigmatized because of its illicit scheduling. However, as research on cannabis use in oncology matures and the stigma begins to fall away, more states are allowing for pharmacist oversight of this product, and its legalization continues to spread. Read More ›

Nancy Brinker vividly recalls her sister, Susan G. Komen, saying those words in the waiting room at MD Anderson Cancer Center in Houston sometime after she received a diagnosis of metastatic breast cancer.

Read More ›

Engaging in advocacy is one of the key responsibilities of patient and nurse navigators, according to Elizabeth Franklin, MSW, from the Cancer Support Community.

Read More ›

Ensuring health literacy is not just about giving patients health information, it is also making sure they’re understanding it, processing it, and able to take action on the information they’ve been given.

Read More ›

An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. He discussed this topic at the NCCN 2019 Hematologic Malignancies meeting. Read More ›

Personalization of therapy in the treatment of patients with myelodysplastic syndrome (MDS) is focused primarily on risk classification of patients. Once clinical risk has been established, treatment considerations should be informed by features such as disease subtype, prognostic somatic mutations, chromosomal abnormalities, targetable somatic mutations, immunologic features, and patient factors, according to Rafael Bejar, MD, PhD, Assistant Professor of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA. Read More ›

San Francisco, CA—People who are less engaged in their own medical care have more negative health consequences, including higher readmission rates, poor care coordination, and less confidence. It is therefore imperative to keep patients engaged in their own healthcare, and current technology plays an important role in achieving this goal, according to Sangeeta Agarawal, RN, CAS, MS, Founder and Chief Executive Officer, Helpsy Health, San Francisco, CA. Read More ›

The human papillomavirus (HPV) has changed the field of head and neck cancer, and HPV now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising in the United States, so is patient curiosity about what sets this cancer apart from other malignancies. Read More ›

We are in a “golden age” in chronic lymphocytic leukemia (CLL), according to Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. Read More ›

Keeping up with the many treatment advances in relapsed or refractory multiple myeloma can be a challenge for even the most informed providers, according to Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia, Dana-­Farber Cancer Institute, Boston, MA. Read More ›

Adolescent and young adult (AYA) patients with cancer consistently indicate the need for better communication from their oncology providers on matters concerning sexual health. Despite misconceptions that the topic may embarrass them or fall on deaf ears, surveys show that AYAs actually want to talk to their providers about topics such as dating, safe sex practices during treatment, contraception, body image, sexuality, fertility, and psychosexual adjustment. Read More ›

The primary reason that nurses cite for not approaching the topic of sexual health with their patients is lack of knowledge. At the Oncology Nursing Society (ONS) 44th Annual Congress, Lisa Chism, DNP, APRN, NCMP, FAANP, Clinical Director, Women’s Wellness Clinic, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, set out to change that by arming oncology nurses with enough knowledge to broach the subject confidently with their female patients. Read More ›

Patients can be taught via neurofeedback to modify their brainwave activity and decrease the sensations of chemotherapy-induced peripheral neuropathy (CIPN), according to Sarah Prinsloo, PhD, LMFT, LPC, Assistant Professor, Department of Palliative, Rehabilitation, and Integrative Medicine, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX. Read More ›

Orlando, FL—Today’s patient with cancer is concerned with more than just cell counts. These patients want to discuss topics such as parenting, financial toxicity, and sex and intimacy, according to Laura Holmes Haddad, author of This Is Cancer, and a cancer survivor. Read More ›

Orlando, FL—Mary Elizabeth Williams, a journalist and author of A Series of Catastrophes and Miracles: A True Story of Love, Science, and Cancer, was one of the first patients in the world to be enrolled in a groundbreaking combination immunotherapy clinical trial, and was one of the first to have a complete response to the treatment used in that trial. She is also white, educated, and privileged, and she openly admits that this played a role in her survival. Read More ›

People who are less engaged in their own medical care have more negative health consequences, including higher readmission rates, poor care coordination, and less confidence. It is therefore imperative to keep patients engaged in their own healthcare, and current technology plays an important role in achieving this goal, according to Sangeeta Agarawal, RN, CAS, MS, Founder and Chief Executive Officer, Helpsy Health, San Francisco, CA. Read More ›

The speed at which the genetics revolution has propelled forward in oncology has created enormous ramifications and unanticipated challenges, according to Suzanne Mahon, RN, DNSc, AOCN, AGN-BC, CNS, Professor, Division of Hematology/Oncology, Department of Internal Medicine, Saint Louis University, MO. Read More ›

Genetic alterations in molecular pathways are involved in tumor development, survival, and progression. Precision cancer medicine is about using the cancer genome to guide treatment decisions, according to Christine M. Walko, PharmD, BCOP, Personalized Medicine Pharmacologist, Personalized Medicine Clinical Service, and Chair, Clinical Genomic Action Committee, Moffitt Cancer Center, Tampa, FL. Read More ›

The increased availability of wearable technologies has enabled patients to track and report their health outcomes, and, in ­theory, has helped healthcare providers manage their patients’ symptoms and utilize resources more effectively. Read More ›

Given the high cost of oncology drugs, it is important for pharmacists to become more business savvy regarding their practices, said Andrea Ledford, PharmD, BCOP, Oncology Pharmacy Manager, Orlando Health UF Health Cancer Center, FL, at the 2019 Hematology/Oncology Pharmacy Association Annual Meeting. Read More ›

“There are a number of ways to go wrong when you’re trying to improve something,” said Kaveh G. Shojania, MD, Director, Centre for Quality Improvement and Patient Safety, University of Toronto, Canada, and Editor-in-Chief, BMJ Quality & Safety, who delivered the keynote address at the 2018 ASCO Quality Care Symposium. Read More ›

There’s really only one way to identify how patients are coping with serious illness: by asking them, according to Thomas J. Smith, MD, FACP, Director of Palliative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD. Read More ›

Although many quality measures exist in oncology, few efforts have been undertaken to prioritize, measure, and report quality and costs for an entire region. A recent multiyear, multistakeholder effort to characterize quality of care and costs for Washington State oncology practices revealed that increased quality may be associated with a reduced cost of care in oncology. Read More ›

Read More ›

Business intelligence is the process of collecting data from disparate systems—internal and external—and turning it into information that is meaningful and actionable toward achieving strategic goals. Read More ›

Patients can be successfully managed with minimal opioid medication after urologic oncology surgery, said Kerri Stevenson, MN, NP-C, RNFA, CWOCN, Lead Advanced Practice Provider – Interventional Radiology, Stanford Health Care, CA, at the 2018 ASCO Quality Care Symposium. Read More ›

Although the cost of care can have severe effects on patients with cancer and their families, oncologists rarely address financial toxicity, according to Hanna K. Sanoff, MD, MPH, Medical Director, University of North Carolina (UNC) NC Cancer Hospital Clinics. Read More ›

New cancer therapies have significantly improved survival outcomes, but have brought with them a wide range of oral toxicities, many of which are class-specific and otherwise new to the field of oncology, according to Nathaniel S. Treister, DMD, DMSc, Division Chief, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA. Read More ›

Bone metastases are exceedingly common among patients with cancer and can significantly affect quality of life. Approximately 65% to 75% of patients with advanced breast or prostate cancer have bone metastases, which can lead to devastating complications, according to Winston Tan, MD, FACP, Chair, Associated Professor of Medicine, Mayo Clinic, Jacksonville, FL. Read More ›

Anxiety is a common symptom in patients with advanced cancer, and is associated with reduced quality of life, increased symptom burden, poor medication adherence, and suboptimal treatment decisions at the end of life. Read More ›

Among patients with cancer, sleep deficiency and cancer-related fatigue rank highest in prevalence and severity during all treatment phases, regardless of cancer type or stage. Read More ›

Omega-3 fatty acids significantly reduced aromatase inhibitor (AI)-induced joint pain in obese women with breast cancer, according to a new retrospective analysis of the SWOG S0927 study, a 24-week, randomized, controlled clinical trial that compared omega-3 fatty acids and placebo in patients with AI-related arthralgia. Read More ›

Read More ›

Utilization management strategies allow payers to manage the cost of healthcare benefits, but according to Ray D. Page, DO, PhD, FACOI, President, the Center for Cancer and Blood Disorders, Weatherford, TX, this practice often leads to burdensome requirements on oncologists and an increased administrative workload. Read More ›

Patients with cancer are increasingly using cannabinoids (the chemical component of cannabis) to treat many symptoms, and a minority of them even take cannabis as a treatment for the cancer itself. Recent surveys have revealed that up to 25% of patients with cancer take some form of cannabis, but oncologists and other medical providers are often unaware that their patients are using medical (or recreational) cannabis. Read More ›

Cancer-related fatigue and insomnia frequently co-occur among patients with cancer, and emerging data have demonstrated that caregivers of patients with cancer also have a high symptom burden, with elevated rates of depression, sleep disturbance, and fatigue Read More ›

Opioids are the mainstay treatment for cancer pain, but managing the opioid crisis in the United States requires an “all hands on deck” approach, according to Tonya Edwards, MS, MSN, FNP-C, Nurse Practitioner, Palliative Care and Rehabilitation Medicine, M.D. Anderson Cancer Center, Houston, TX. Read More ›

The incidence of sexual dysfunction in cancer survivors can be high and long lasting, but early discussion, evaluation, and treatment of sexual problems can improve sexual outcomes, reduce emotional distress, and facilitate recovery in survivors. Read More ›

In April 2017, the FDA approved midostaurin (Rydapt) as the first tyrosine kinase inhibitor (TKI) for acute myeloid leukemia (AML) with a specific biomarker, FLT3 mutation, marking the introduction of targeted therapy for this notoriously difficult-to-treat type of leukemia. Read More ›

Cancer care is not cheap, but for young adults with cancer, the cost of care goes far beyond medical bills, according to ­Samantha Watson, MBA, 2-time young adult cancer survivor and Co-Founder and CEO of the Samfund. Few resources in the United States are dedicated specifically to helping patients recover financially from cancer. Read More ›

Approximately 25% of women with gynecologic malignancies cannot afford the cost of their medical care, according to a study presented at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›

Participation in clinical trials may help to overcome health disparities in the treatment of advanced or recurrent ovarian cancer, and minority patients should be encouraged to participate, said Khilen B. Patel, MD, Obstetrics & Gynecology Resident, Medical College of Georgia, Augusta University, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›

Read More ›

Many cancer survivors do not meet general recommendations for diet and exercise because of a multitude of common barriers, according to Erin Van Blarigan, ScD, Assistant Professor, Departments of Epidemiology & Biostatistics and Urology, University of California, San Francisco. Read More ›

Read More ›

Read More ›

Because of the novel mechanisms of action of immunotherapies, extended treatment period, and unique toxicities, cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint, suggested Katy K. Tsai, MD, Clinical Instructor, Division of Hematology/Oncology, University of California, San Francisco (UCSF), at the 2018 Cancer Survivorship Symposium. Read More ›

Read More ›

Read More ›

Discussions about prognosis, transitions to palliative care, and the end of life are—to say the least—challenging for patients and providers. But effective, honest, and supportive communications are keys to good clinical care and informed decision-making, according to Dame Lesley Fallowfield, FMedSci, DPhil, Professor of Psycho Oncology, Sussex Health Outcomes Research & Education in Cancer, University of Sussex, Brighton, England. Read More ›

Read More ›

There is only one “king of the road” when it comes to dealing with the adverse side effects of oral cancer drugs, and that is not the healthcare professional, according to Christine B. Boers-Doets, MSc, of the Netherlands Leiden University Medical Center, author of The TARGET System, and creator of the 7 Pillars of Ultimate Drug Success formula. Read More ›

It is well known that cancer treatment is often associated with serious adverse side effects, but conventional care is often focused on cure and survival, rather than on a holistic approach to patient care, suggests Nerissa Wood, BSN, RN, OCN, Director, Tulane Comprehensive Cancer Clinic, New Orleans, LA. Read More ›

To effectively address socioeconomic disparities in healthcare, particularly regarding cancer survivorship, it is critical that we improve our understanding of the material, psychosocial, and behavioral dimensions of financial well-being, said Reginald D. Tucker-Seeley, MA, ScM, ScD, Edward L. Schneider Chair in Gerontology, University of Southern California, Los Angeles, at the 2017 AACR Science of Cancer Health Disparities Conference. Read More ›

The number of cancer survivors is increasing. To keep up with this trend, survivorship care must evolve and become more efficient, insists Jennifer R. Klemp, PhD, MPH, MA, Director, Cancer Survivorship, University of Kansas Cancer Center, Westwood. Read More ›

An American Society of Clinical Oncology (ASCO) Oncology Practice Trends Survey from 2015 to 2016 revealed that increasing practice or facility expenses, drug pricing, and issues with electronic health records (EHRs) were among the top practice pressures cited by oncologists. Read More ›

By now all oncologists know that the implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is shifting physician reimbursement from a volume- to a value-based model. To succeed with MACRA, practices must become familiar with how this will affect them and get ready to incorporate the new measures to ensure they get the best level of reimbursement under this program. Read More ›

Integrating research findings and clinical trial evidence into healthcare policy and clinical practice is not always simple, according to David Chambers, DPhil, MSc, Deputy Director for Implementation Science, Division of Cancer Control and Population Sciences, National Cancer Institute, at the 2017 Quality Care Symposium. Read More ›

Whether delivered under the umbrella of palliative care, supportive care, or psychosocial oncology, these types of services strengthen the feelings of meaning, value, and dignity in patients with cancer, says Scott A. Irwin, MD, PhD, Director, Supportive Care Services, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA. Read More ›

The number one stressor for patients with cancer is no longer the fear of dying from their disease; rather, it is fear of their financial obligations because of treatment, said Dan Sherman, MA, LPC, Founder and President, the NaVectis Group, at the 2017 Quality Care Symposium. Read More ›

Movement on the American Health Care Act may continue, and the evolution of the Affordable Care Act (ACA) is not known, said Elizabeth Carpenter, Senior Vice President, Avalere Health, at the 2017 Association of Community Cancer Centers meeting. Read More ›

A change in leadership brings with it healthcare reform and potential changes in drug pricing in the United States, said Jessica Turgon, MBA, Principal, ECG Management Consultants, Washington, DC, at the 2017 Association of Community Cancer Centers meeting. Ms Turgon discussed what this transition of power means for cancer centers, and what oncology providers can realistically expect under the Trump administration. Read More ›

Read More ›

With the release of the final rule of the Medicare Access and CHIP Reauthorization Act (MACRA), participating providers will now be reimbursed by the Centers for Medicare & Medicaid Services (CMS) based on the quality of the care they provide rather than on the volume. Read More ›

The Oncology Care Model (OCM) is a physician-led specialty care model that is aimed at providing higher quality, more highly coordinated oncology care at the same or lower cost to Medicare beneficiaries. Read More ›

he cost of cancer care is rising quickly, and, as a result, oncology is moving away from the fee-for-service payment model toward the Oncology Care Model (OCM). Read More ›

The American Society of Clinical Oncology (ASCO) has developed a proposal for an Alternative Payment Model that is focused on delivering value in oncology and supporting higher-quality and more affordable cancer care. Read More ›

Read More ›

“Are we really measuring quality, or are we measuring our ability to report?” asked Brian R. Bourbeau, MBA, Director, Practice Operations, Oncology Hematology Care, the US Oncology Network, Cincinnati, OH. “So far it’s been the latter,” he said. Read More ›

Read More ›

Burnout is a syndrome that includes feeling exhausted, cynical, and ineffective at work. Recognizing the triad of symptoms in the oncology setting is the first step to identifying physician burnout, said Anthony L. Back, MD, Professor, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, at ASCO’s first Oncology Practice Conference in March 2017. Read More ›

To improve the quality of cancer care, the voices of patients with cancer should be integrated into care delivery and evaluation, said Neeraj K. Arora, PhD, Associate Director, Healthcare Delivery and Disparities Research, Patient-Centered Outcomes Research Institute, Washington, DC, at the 2017 ASCO Quality Care Symposium. Read More ›

The term “patient-reported outcome” has become ubiquitous in cancer care. Patient-reported outcomes (PROs) are still in the early stages of being integrated into quality assessment programs and routine clinical practice, but engaging patients through PROs can be an invaluable tool for assessing and improving the quality of symptom management, said Ethan M. Basch, MD, MSc, FASCO, Director, Cancer Outcomes Research Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, at the 2017 ASCO Quality Care Symposium. Read More ›

Establishing a Patient and Family Advisory Council for Quality (PFACQ) is one of the most direct routes to true patient-centered care, said Kate Niehaus, MBA, Chair, PFACQ, Memorial Sloan Kettering Cancer Center (MSKCC), New York City, at the 2017 ASCO Quality Care Symposium. Ms Niehaus discussed how PFACQs can be used as a mechanism for the patient’s voice. Read More ›

Telemedicine, or the remote diagnosis and treatment of patients by means of telecommunications technology, is now at the forefront of efficient healthcare delivery. This fundamental change in the delivery of healthcare focuses on bringing medicine to the patient rather than bringing the patient to medicine. Read More ›

Successful negotiations are critical to sustaining a business and retaining key customers, including in oncology practices, suggested Steven L. D’Amato, BSPharm, BCOP, RPh, Executive Director, New England Cancer Specialists, at ASCO’s first Oncology Practice Conference in March 2017. Read More ›

Value-based care—the best care delivered at the lowest cost—is here to stay, said Karen K. Fields, MD, Medical Director, Clinical Pathways and Value-Based Cancer Care, Moffitt Cancer Center, Tampa, FL, at ASCO’s first Oncology Practice Conference in March 2017. Read More ›

Clinical pathways have become a central component of medical oncology practice and a cornerstone of future reimbursement methodologies and quality-of-life efforts, according to Robin Zon, MD, FACP, Medical Oncologist, Michiana Hematology Oncology, IN, and Chair, ASCO Task Force on Clinical Pathways. Read More ›

Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York. Read More ›

Value frameworks in oncology are relatively early in development, and their ultimate impact remains unknown, but at a minimum, providers should be aware of the current value frameworks and how each value framework measures value, as well as their implications for clinical trial development, said Kasia Shields, PharmD, MBA, BCOP, BCPS, Director, Medical Communications, Xcenda/AmerisourceBergen, at the 2016 Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program. Read More ›

Read More ›

Read More ›

Read More ›

Read More ›

Read More ›

Read More ›

Read More ›

Read More ›

A clear set of standard operating procedures is at the heart of US Pharmacopeial Convention Chapter 800 (USP 800) compliance, according to Carol Yarrington, PharmD, BCOP, Oncology and Infusion Pharmacy Coordinator and Clinical Oncology Pharmacist, St. Joseph Mercy Health System, Ann Arbor, MI. At the recent Hematology/Oncology Pharmacy Association’s Oncology Pharmacy Practice Management Program conference, Dr Yarrington provided tips on how to address the new standard. Read More ›

In-house pharmacies eliminate many of the unnecessary barriers to optimal cancer care presented by specialty pharmacies, while also providing higher-quality care to patients receiving oral cancer drugs, said presenters at a patient advocacy session at the 2016 Community Oncology Alliance (COA) meeting. Read More ›

Web-based reporting in the outpatient community setting is not only feasible, but it can identify areas that need quality improvement initiatives, according to J. Russell Hoverman, MD, PhD, Vice President of Quality Programs, Texas Oncology, PA, Dallas. Read More ›

Secondary pathology review can significantly improve clinical outcomes through precise and accurate pathology diagnoses, according to Lavinia P. Middleton, MD, Professor, Department of Pathology, M.D. Anderson Cancer Center, Houston, TX. Read More ›

Patients with cancer increasingly wish to discuss costs with their oncologists, whose knowledge of treatment costs is limited. At the 2016 ASCO Quality Care Symposium, Nora B. Henrikson, PhD, MPH, of Group Health Research Institute, Seattle, WA, presented the results from a pilot project called OPT-IN, which aims at increasing clinician access to treatment prices in the clinical setting. Read More ›

Read More ›

At the 2016 Community Oncology Alliance conference, Patricia J. Goldsmith, Chief Executive Officer of CancerCare, and Alan J. Balch, PhD, Chief Executive Officer of the Patient Advocate Foundation (PAF), discussed the services their organizations provide for patients, highlighting the cost barriers for patients with cancer. Read More ›

Read More ›

The first oncology biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin. Read More ›

Read More ›

Aggregated real-time data provide the tools to rapidly identify opportunities for the improvement of delivered services and for the initiation of quality improvement projects. Enhanced information technology capabilities, such as the iRiS software app, are foundational for practice transformation to future value-based cancer care models, according to John D. Sprandio, Sr, MD, Chief Physician, Consultants in Medical Oncology and Hematology (CMOH), Drexel Hill, PA. Read More ›

Family- and patient-related factors were identified as the most significant barriers to early end-of-life discussions, as well as to the timely discontinuation of cancer-directed therapies in the palliative setting, according to the results of a multicenter survey of oncologists in Ontario, Canada. Read More ›

Read More ›